Skye Bioscience announced on Monday that its obesity drug candidate has failed to demonstrate significant weight loss in a mid-stage clinical trial, raising concerns about the viability of its controversial therapeutic approach. The drug, which functions as an antibody blocking CB1 receptors, resulted in an average weight loss of only 1.5% over a 26-week period, a result deemed statistically insignificant when compared to the placebo group.
This setback comes at a critical juncture for Skye, as the company had positioned this drug as a potential game-changer in obesity treatment. Preliminary analyses indicated that patients experienced lower than anticipated drug exposure, suggesting that higher dosing might be necessary to achieve the desired outcomes. Skye is currently evaluating its data to determine the feasibility of conducting an additional Phase 2 study, which could influence its future development strategies and partnerships.
Start your 7-day trial and see what the database can do →
